本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-055 美康生物科技股份有限公司 近日，美康生物科技股份有限公司（以下简称"公司"）的控股子公司江西 美康盛德生物科技有限公司（以下简称"江西美康"）取得了由江西省药品监督 管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》（以下简称 "《注册证》"），具体情况如下： 关于控股子公司取得医疗器械注册证的公告 美康生物科技股份有限公司 上述《注册证》的取得，丰富了公司在体外诊断化学发光细分领域产品线的 品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营 将产生积极影响。上述产品实际销售情况取决于未来市场推广效果，公司目前尚 无法预测其对公司未来业绩的影响，敬请投资者注意投资风险。 三、备查文件 《中华人民共和国医疗器械注册证（体外诊断试剂）》。 | 序号 | 注册人名称 | 产品名称 | 注册证编号 | 注册证有效期间 | | 预期用途 | | --- | --- | --- | --- | -- ...

格隆汇9月12日丨美康生物(300439.SZ)公布，全资子公司宁波美康盛德生物科技有限公司(简称"盛德生 物")于近日取得了由浙江省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，产品名称：色 谱柱。上述《注册证》的取得，丰富了公司在体外诊断质谱细分领域产品线的品种，有利于进一步提升 公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-054 美康生物科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司(以下简称"公司")的全资子公司宁波美康盛德 生物科技有限公司(以下简称"盛德生物")于近日取得了由浙江省药品监督管理 局颁发的《中华人民共和国医疗器械注册证》（以下简称"《注册证》"），具 体情况如下： 一、医疗器械注册证的具体情况 | 序号 | 注册人名称 | 产品名称 | | 注册证编号 | | 注册证有效期间 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 盛德生物 | 色谱柱 | 浙械注准 | 20252221668 | 2025 2030 | 年 9 月 年 月 9 | 4 日至 日 3 | 与液相色谱系统或液相色谱串联 质谱系统配套使用，用于对人体样 本中被测物进行分离。 | 二、对公司业绩的影响及风险提示 上述《注册 ...

（编辑 袁冠琳） 证券日报网讯 美康生物9月5日在互动平台回答投资者提问时表示，公司持续深化国际化战略，积极布 局海外市场，将继续提升国际销售团队素质及业务能力，加快推进产品国际市场注册及认证，提升企业 在国际市场的综合实力。 ...

Core Viewpoint - Meikang Bio announced on September 5 that as of June 30, 2025, the number of its shareholders will be 25,679 [2] Company Summary - The company is actively engaging with investors through interactive platforms [2] - The projected number of shareholders indicates a growing interest in the company [2]

Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]

Group 1 - The core point of the article is that Meikang Bio has announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained a medical device registration certificate for in vitro diagnostic reagents from the Jiangxi Provincial Drug Administration [2] Group 2 - The registration certificate is a significant regulatory approval that may enhance the company's product offerings in the medical device sector [2] - This development indicates the company's ongoing efforts to expand its presence in the biotechnology industry [2] - The approval could potentially lead to increased revenue opportunities for the company through the commercialization of its diagnostic products [2]

Group 1 - Meikang Bio's subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate from the Jiangxi Provincial Drug Administration for products including the "Trace Element Testing Kit" [1] - For the fiscal year 2024, Meikang Bio's revenue composition will be 100% from medical devices [1] - As of the report date, Meikang Bio has a market capitalization of 4.1 billion yuan [1]

上述《注册证》的取得，丰富了公司在体外诊断质谱及POCT细分领域产品线的品种，有利于进一步提 升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。 美康生物(300439.SZ)发布公告，公司的控股子公司江西美康盛德生物科技有限公司(简称"江西美康")取 得了由江西省药品监督管理局颁发的《中华人民共和国医疗器械注册证(体外诊断试剂)》，产品名称： 微量元素检测试剂盒(电感耦合等离子体质谱法)、微量元素质控品、尿酸/肌酐/尿素检测试剂盒(干化学 法)。 ...

美康生物科技股份有限公司 | | | | | | | | | | | 美康生物科技股份有限公司 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 证券代码：300439 | | | 证券简称：美康生物 | | | | | | | | | | | 公告编号：2025- | | 053 | | | | | | | | | | | | | | | | | 美康生物科技股份有限公司 | | | | | | | | | | | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 | | | | | | | | | | | | | | | | 假记载、误导性陈述或重大遗漏。 | | | | | | | | | | | | | | | | 近日，美康生物科技股份有限公司（以下简称"公司"）的控股子公司江西 | | | | | | | | | | | | | | | | 美康盛德生物科技有限公司（以下简称"江西美康"）取得了由江西省药品监督 ...